Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung Cancer

Stage IV NSCLC Clinical Trial

Official title:
An Open Label Safety and Exploratory Efficacy Study of Kanglaite Injection in Patients Having Progressive Stage IV NSCLC Who Are Not Candidates for Other Anti-cancer Treatment

Status Terminated

Clinical Trial Summary

This study is for patients with advanced non small cell lung cancer that has progressed despite standard of care. The purpose of the study is to see if Kanglaite injection has any effect on survival.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Stage IV NSCLC

Clinical Trial Details

NCT number	NCT01640730
Study type	Interventional
Source	KangLaiTe USA
Contact
Status	Terminated
Phase	Phase 2
Start date	May 2012
Completion date	October 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01438307` - Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer	Phase 2
Not yet recruiting	`NCT05988697` - Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib
Completed	`NCT01864681` - Combination of Metformin With Gefitinib to Treat NSCLC	Phase 2
Not yet recruiting	`NCT06064279` - Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC	Phase 1/Phase 2
Completed	`NCT03812549` - Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients	Phase 1
Recruiting	`NCT05631574` - Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer	Phase 1